Avadel Shareholders Wake Up To A Competing Bid For Their Shares
Source: SeekingAlpha
2025-11-14 11:50:32 ET
Not only has biotech M&A activity picked up recently, but we now have at least two potentially contentious transactions in the space. Following Novo Nordisk A/S's ( NVO ) decision to fight Pfizer Inc. ( PFE ) for obesity drug developer Metsera, Inc. ( MTSR ), we now have Danish pharmaceutical company H. Lundbeck A/S ( OTCPK:HLUBF ) ( OTCPK:HLBBF ) (HLUN-A.CO) (HLUN-B.CO) coming in with a higher bid for Avadel Pharmaceuticals plc ( AVDL ) despite a standing agreement between this developer of narcolepsy drugs and Alkermes plc ( ALKS )....
Read the full article on Seeking Alpha
For further details see:
Avadel Shareholders Wake Up To A Competing Bid For Their Shares
H. Lundbeck
NASDAQ: HLBBF
HLBBF Trading
0.0% G/L:
$6.2075 Last:
100 Volume:
$6.2075 Open:
